

Ansell Limited A.B.N. 89 004 085 330

Level 3, 678 Victoria Street Richmond, Victoria 3121, Australia

> GPO Box 772 Melbourne Victoria 3001, Australia

Telephone (+613) 9270 7270 Facsimile (+613) 9270 7300 <u>www.ansell.com</u>

21 September 2012

Manager Companies
Company Announcements Office
Australian Securities Exchange Limited
Level 4, Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

2012 Highlights Flyer

In accordance with Listing Rule 3.17, attached is a copy of the 2012 Highlights Flyer to be sent to shareholders who do not receive a hard copy of the Annual Report 2012.

Yours sincerely,

Craig M Cameron
Company Secretary





Highlights - Year ended 30 June 2012

- · Three exciting acquisitions made during the year, Sandel Medical Industries, Shanghai Feidun Trading Company and Trelleborg Protective Products.
- · Ansell's global footprint, including its growing presence in Emerging Markets, proved highly resilient in a very difficult environment.
- Sales in Emerging Markets represented 24 per cent of total sales, compared to 21 per cent in the previous year.
- EBIT of US\$153.2 million was up 12 per cent on the previous year.
- Profit attributable to shareholders of US\$133.0 million, a 9 per cent increase on the previous year.
- Earnings per share was US101.4 cents, an increase of 11 per cent on the previous year.
- · Balance sheet continues to strengthen and free cash flow remains very strong.
- FY2012 total dividend increased by 9 per cent to 35.5 cents per share.
- · Important new product launches were made such as the Hyflex® ultra-light cut resistant glove, ActivArmr® flame resistant gloves, VersaTouch™ cut protection gloves and SKYN® extra lubricated condoms.

Results in Summary	Reported in Australian Dollars			Reported in Operating Currency - US Dollars			
	FY11 A\$M	FY12 A\$M	%	FY11 US\$M	FY12 US\$M	%	
Sales	1,219.8	1,218.3	-	1,206.9	1,255.3	+ 4	
EBIT	138.8	149.4	+ 8	136.9	153.2	+ 12	
Profit Attributable	122.7	130.0	+ 6	121.7	133.0	+ 9	
Earnings per share (¢)	92.4	99.1	+ 7	91.6	101.4	+ 11	
Dividend (¢)	33.0	35.5	+ 8				

Business Review

Ansell achieved strong US dollar results with double digit increases in EBIT and EPS despite sales growth being inhibited by challenges faced in the first half with the new Fusion ERP implementation in the North American and Latin America/Caribbean regions and the second half slowdown in Europe. Ansell's global footprint, including its growing presence in Emerging Markets, proved highly resilient in a very difficult environment.

Sales for the year increased 4 per cent with Sexual Wellness and Industrial producing high single digit growth, and Specialty Markets and Medical being more or less flat as they both shed lower margin sales.

Ansell's 12 per cent increase in EBIT came from volume growth, a better sales mix, and pricing - offset by higher input costs and extra ERP implementation costs. Sexual Wellness was the outstanding contributor with EBIT up 52 per cent.

We made three exciting acquisitions this year: Sandel Medical, Shanghai Feidun and Trelleborg Protective Products. Sandel Medical has been with us for over a year now, its products are being rolled out globally and its EBIT performance is ahead of expectations. Shanghai Feidun provides better control of condom distribution in the Shanghai area and is also performing as expected. Finally, Ansell Protective Solutions (renamed from Trelleborg) is being rapidly integrated and leveraged to strengthen our position in the first responders and military verticals.

Significant investment continued to be made in additional sales positions and field infrastructure, higher marketing spending and increased spending on new product development and investment to improve the effectiveness of our manufacturing operations.

Magnus Nicolin, Managing Director and CEO









Increase in EBIT in US\$

Increase in Profit Attributable in US\$

Increase in Earnings per Share in US\$

Increase in FY2012 Dividend to 35.5¢ per share

Comasec SAS acquisition

On 7 August 2012, Ansell announced an agreement to acquire Comasec SAS and its subsidiaries for a (cash-free, debt-free) purchase price of EUR101.5 million (A\$118 million), which is being funded out of Ansell's available cash and credit facilities. This is Ansell's largest acquisition for many years.

Comasec is a privately owned French group with sales of around EUR100 million (around \$124 millon), manufacturing operations in Portugal and Malaysia and over 1,200 employees globally. Comasec is a significant participant in the European personal protective equipment market and specialises in gloves for chemical protection, food handling, cut protection, mechanical protection, dry box and thermal protection. Major brands are Comasec®, Marigold®, and Marigold Industrial®.

Settlement of the acquisition is expected by October 2012, subject to regulatory approvals.

Global Business Unit (GBU) Results



Industrial accounted for 40 per cent of Revenue and 51 per cent of Segment EBIT

Sales rose 7 per cent, despite
North American (NA) Fusion ERP
implementation issues and European
economic pressures, with the Latin
America/Caribbean and Asia Pacific
regions delivering double digit increases.
There was a strong second half recovery
in NA and LAC and this key business
remains on solid ground with the three

core glove brands (HyFlex®, TNT® and AlphaTec®) all doing well.

Ramped up investment in sales and marketing spending across the regions, increased investment in the Industrial GBU's research and development expertise and additional sales people and infrastructure in key Emerging Markets, will provide solid future returns.

The pace of new product releases is expected to pick up in the 2013 financial year and the new research and development centre in Sri Lanka is now operational.



Medical accounted for 28 per cent of Revenue and 24 per cent of Segment EBIT

The 2012 financial year was a challenging year for the Medical business. Ansell continued to exit from natural rubber latex exam gloves, with volumes falling 38 per cent. Surgical gloves sales rose 3 per cent, with synthetic volumes growing a strong 17 per cent.

Nevertheless, some EBIT growth was

achieved as better product mix and higher contributions from surgical safety products offset additional (Fusion related) NA distribution expenses, higher year-on-year natural rubber latex costs and SG&A growth.

Sandel Medical, an innovator in surgical safety solutions, had a solid first year, with its EBIT performance ahead of expectations. Strong growth is expected with the core ranges now being launched globally and many additional new product releases in the 2103 financial year. In addition, a number of new surgical glove launches are planned in the 2013 financial year, under the core Gammex®, Encore® and Medi-Grip® brands.



Specialty Markets accounted for 14 per cent of Revenue and 4 per cent of Segment EBIT

Sales were up 1 per cent as continued strong Construction/DIY and Chemical/Liquid Handling growth was offset by lost low margin Food Service sales (mostly Fusion related) and delayed renewals of some US military contracts. Portfolio optimisation via a balance of SKU rationalisation and new product introduction continued.

EBIT was up strongly year-on-year benefiting from the improving sales mix as well as increases in pricing.

Investment in organic growth continued and the acquisition of Trelleborg Protective Products (now called Ansell Protective Solutions) provided the Specialty Markets GBU with added capabilities and expansion into a personal protective equipment adjacency (clothing) and a priority vertical (first responders).

New product releases accelerated sharply in the 2012 financial year with extensions to the ActivArmr®, VersaTouch™ and ProjeX® glove ranges and this trend is expected to continue in the 2013 financial year.



SEXUAL WELLNESS

Sexual Wellness accounted for 18 per cent of Revenue and 21 per cent of Segment EBIT

Sales were up 8 per cent driven by condom line extensions (SKYN® and Zero®), strong Emerging Markets growth and 24 per cent growth in the lubricants/devices/other category. SKYN® continues to drive this business and during the 2012 financial year the range was extended with the SKYN® large and SKYN® Extra Lubricated

releases. In addition, a major promotional program was undertaken globally with very positive results.

EBIT was up 52 per cent even after a year-on-year \$1.3 million increase in restructuring costs. GPADE margins rose strongly, due to product mix and operational improvements, and more than offset continued investment in sales and marketing, people and programs.

New product introductions picked up in the 2012 financial year and should accelerate further in 2013 with the release of the 'ameleTM' female intimate freshness range as well as many new condom offerings.

FY2013 Outlook

The Company's clear objective is to continue its profitable expansion both organically and by using the strength of its balance sheet to create further shareholder value.

In a difficult global economic environment, Ansell continues to see opportunities to grow both by acquisition and organically, especially in Emerging Markets where the Company now makes almost a quarter of its revenue, execute acquisition opportunities and continue to reshape itself into a more agile and growth oriented competitor.

As at the date of this report, we are encouraged by the sales and profit momentum that has been carried into the 2013 financial year, we are also pleased to note that we have received all approvals to close the Comasec deal by October 2012 and we are seeing good results from many of our new product launches.